Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Importance In 2 trials enrolling patients with heart failure (HF) across the spectrum of
ejection fraction (EF), dapagliflozin has been shown to reduce the rate of the composite of …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Background: The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies …

Importance Women may respond differently to certain treatments for heart failure (HF) with
reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …

Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …

Importance Dapagliflozin was recently shown to reduce cardiovascular death or worsening
heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …

Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …

Drug therapies for people with heart failure and preserved ejection fraction (HFpEF) are
often limited to diuretics to improve symptoms as no therapies demonstrate a mortality …